| Metric | Value ($ M) | Q1 FY25 |
|---|---|---|
| Revenue | 20.03 | 15.1% |
| Total Income | 20.03 | 15.1% |
| Expenditure | 46.10 | 10.5% |
| PBT | -32.97 | 14.2% |
| Net Profit | -32.97 | 14.6% |
| OPM | — | |
| NPM | — | |
| EPS | -0.21 | 41.7% |
ADC Therapeutics Reports Q1 2026 Net Product Revenue of $20.0 Million
04 May 2026 · 4 May, 5:17 pm
Summary
ADC Therapeutics reported financial results for the first quarter ended March 31, 2026. Net product revenues were $20.0 million, compared to $17.4 million for the first quarter of 2025. The company's cash and cash equivalents were $231.0 million as of March 31, 2026, providing an expected cash runway at least into 2028. The company anticipates topline results from LOTIS-5 in the second quarter of 2026 and full data for LOTIS-5 and LOTIS-7 by year end.
Key Highlights
- 1
ADC Therapeutics reported first quarter 2026 net product revenue of $20.0 million.
- 2
License revenues and royalties were $0.8 million for the first quarter of 2026.
- 3
Research and Development expense decreased to $19.9 million for the first quarter of 2026.
- 4
Net loss for the first quarter of 2026 was $33.0 million, or a net loss of $0.21 per basic and diluted share.
- 5
As of March 31, 2026, cash and cash equivalents were $231.0 million, with an expected cash runway at least into 2028.
- 6
The company anticipates LOTIS-5 topline results in the second quarter of 2026 and full data for LOTIS-5 and LOTIS-7 by year end.
Management Comments
Ameet Mallik
“During the first quarter, we continued to build momentum across our ZYNLONTA program." “Looking ahead, we have multiple near-term catalysts, including topline results from LOTIS-5 anticipated in the second quarter, full results expected from both LOTIS-5 and LOTIS-7 by year-end, as well as additional updates from the investigator-initiated studies in indolent lymphomas ahead. We believe that we are well-positioned to expand ZYNLONTA’s role across B-cell malignancies, accelerating our expected growth trajectory starting in 2027.”
Informational and educational content only. Not investment advice.